<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CTJ</journal-id>
<journal-id journal-id-type="hwp">spctj</journal-id>
<journal-id journal-id-type="nlm-ta">Clin Trials</journal-id>
<journal-title>Clinical Trials</journal-title>
<issn pub-type="ppub">1740-7745</issn>
<issn pub-type="epub">1740-7753</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1740774513478229</article-id>
<article-id pub-id-type="publisher-id">10.1177_1740774513478229</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Evaluating and utilizing probability of study success in clinical development</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Wang</surname><given-names>Yanping</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Fu</surname><given-names>Haoda</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Kulkarni</surname><given-names>Pandurang</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Kaiser</surname><given-names>Christopher</given-names></name>
</contrib>
<aff id="aff1-1740774513478229">Eli Lilly and Company, Indianapolis, IN, USA</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-1740774513478229">Yanping Wang, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. Email: <email>wang_yanping@lilly.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2013</year>
</pub-date>
<volume>10</volume>
<issue>3</issue>
<fpage>407</fpage>
<lpage>413</lpage>
<permissions>
<copyright-statement>© The Author(s), 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">The Society for Clinical Trials</copyright-holder>
</permissions>
<abstract>
<sec id="section1-1740774513478229">
<title>Background</title>
<p>Drug development has become increasingly costly, lengthy, and risky. The call for better decision making in research and development has never been stronger. Analytic tools that utilize available data can inform decision makers of the risks and benefits of various decisions, which could lead to better and more informed decisions.</p>
</sec>
<sec id="section2-1740774513478229">
<title>Purpose</title>
<p>Through some real oncology examples, we will demonstrate how using available data to analytically evaluate probability of study success (PrSS) can lead to better decisions in clinical development.</p>
</sec>
<sec id="section3-1740774513478229">
<title>Methods</title>
<p>The predictive power, or average conditional power, is used to quantify the PrSS. To calculate the probability, we follow a general two-step process: (1) use Bayesian modeling and appropriate assumptions to synthesize relevant data to derive the distribution of treatment effect and (2) evaluate the PrSS analytically or via trial simulation.</p>
</sec>
<sec id="section4-1740774513478229">
<title>Results</title>
<p>We applied the procedure to several compounds in our oncology pipeline. The analysis informed decision making where PrSS was an important factor to consider.</p>
</sec>
<sec id="section5-1740774513478229">
<title>Limitations</title>
<p>When modeling the treatment effect, we made certain assumptions, including how two drugs work together and exchangeable treatment effects across studies. Those assumptions are reasonable for our specific situations but may not generalize well.</p>
</sec>
<sec id="section6-1740774513478229">
<title>Conclusions</title>
<p>From our experience, PrSS based on available data can help decision making in drug development, particularly the Go/No-Go decision after the proof of concept trial is completed. When applicable, we recommend this evaluation be regularly done in addition to the routine data analysis for clinical trials.</p>
</sec>
</abstract>
</article-meta>
</front>
<body>
<sec id="section7-1740774513478229" sec-type="intro">
<title>Introduction</title>
<p>Clinical studies in oncology, particularly phase III (ph3) studies, are lengthy and costly, but extremely important, as they often deal with treating patients with potentially life-ending cancers. However, the failure rate of clinical studies is high [<xref ref-type="bibr" rid="bibr1-1740774513478229">1</xref>]. For example, only 34% of ph3 oncology trials with results reported from 2003 through 2010 were successful [<xref ref-type="bibr" rid="bibr2-1740774513478229">2</xref>]. Therefore, a critical question that study sponsors always ask before investing in a clinical study is how likely the study will be successful. Traditional statistical power does not provide a reliable answer to this question – most ph3 studies are powered at 80% or higher, but the success rate of ph3 studies is much lower than 80%. This is so because power is the probability of success (achieving statistical significance) at an assumed effect size. The assumed effect size is often based on regulatory, payer, and/or marketing requirements or needs, and may not be supported by available evidence or reflect the true treatment effect. Occasionally, the effect size is estimated from available evidence, but the estimate is typically treated as a fixed constant without any variability. In short, not utilizing available data or not utilizing the data appropriately is the underlying reason that power does not reliably measure the probability of study success (PrSS).</p>
<p>Several authors have proposed to use ‘assurance’, ‘expected power’, or ‘average success probability’ to quantify PrSS [<xref ref-type="bibr" rid="bibr3-1740774513478229">3</xref>,<xref ref-type="bibr" rid="bibr4-1740774513478229">4</xref>]. The idea is to use available data to derive the distribution of the unknown true treatment effect and then average the power function of the new study over the distribution. The resulting average is nothing but the so-called predictive power, a hybrid of frequentist and Bayesian concepts [<xref ref-type="bibr" rid="bibr5-1740774513478229">5</xref>,<xref ref-type="bibr" rid="bibr6-1740774513478229">6</xref>]. The quantity (referred to as PrSS in this article) is based on available data and also accounts for the uncertainty in our current knowledge on the treatment effect, thus representing an improvement over power in quantifying the likelihood of success for the new study.</p>
<p>In this article, we will illustrate how we evaluated the PrSS for some real studies in oncology and demonstrate how the PrSS evaluation could help improve study designs and inform decision making in drug development. The rest of the article is organized as follows: In the Methods section, we will lay out the procedure to evaluate PrSS, three real examples will be shared in the Applications section, and we will then conclude the article with a brief discussion.</p>
</sec>
<sec id="section8-1740774513478229" sec-type="methods">
<title>Methods</title>
<p>We denote the treatment effect, relative to the control, by Δ. Then the PrSS of a new study, conditional on available data, is simply given as</p>
<p>
<disp-formula id="disp-formula1-1740774513478229">
<label>(1)</label>
<mml:math display="block" id="math1-1740774513478229">
<mml:mrow>
<mml:mtext>PrSS</mml:mtext>
<mml:mo>=</mml:mo>
<mml:mo>∫</mml:mo>
<mml:mtext>P</mml:mtext>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mtext>study</mml:mtext>
<mml:mspace width="0.25em"/>
<mml:mtext>success</mml:mtext>
<mml:mo stretchy="false">|</mml:mo>
<mml:mi>Δ</mml:mi>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mtext>P</mml:mtext>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mi>Δ</mml:mi>
<mml:mo stretchy="false">|</mml:mo>
<mml:mtext>data</mml:mtext>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mtext>d</mml:mtext>
<mml:mi>Δ</mml:mi>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula1-1740774513478229" xlink:href="10.1177_1740774513478229-eq1.tif"/>
</disp-formula>
</p>
<p>So far, we have implied study success as achieving a prespecified threshold for p-value (such as 5% for a 2-sided test or 2.5% for 1-sided). This definition can certainly be modified as needed. For example, one may define study success as a significant p-value with the estimated treatment effect above a certain threshold. For the ease of presentation, in this article, we will focus on achieving a 1-sided p-value of less than 2.5% unless otherwise noted. Consequently, <inline-formula id="inline-formula1-1740774513478229"><mml:math display="inline" id="math2-1740774513478229"><mml:mrow><mml:mtext>P</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mtext>study</mml:mtext><mml:mspace width="0.25em"/><mml:mtext>success</mml:mtext><mml:mo stretchy="false">|</mml:mo><mml:mi>Δ</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> is just the traditional statistical power at Δ. In <xref ref-type="disp-formula" rid="disp-formula1-1740774513478229">Equation (1)</xref>, <inline-formula id="inline-formula2-1740774513478229"><mml:math display="inline" id="math3-1740774513478229"><mml:mrow><mml:mtext>P</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mi>Δ</mml:mi><mml:mo stretchy="false">|</mml:mo><mml:mtext>data</mml:mtext><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> describes the posterior distribution of treatment effect given available data. This posterior distribution becomes the prior distribution for the new study under evaluation. We choose to use Bayesian modeling to derive <inline-formula id="inline-formula3-1740774513478229"><mml:math display="inline" id="math4-1740774513478229"><mml:mrow><mml:mtext>P</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mi>Δ</mml:mi><mml:mo stretchy="false">|</mml:mo><mml:mtext>data</mml:mtext><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> as it offers more flexibility to synthesize available data that comes from different studies and/or in different forms.</p>
<p>Analytical evaluation of <xref ref-type="disp-formula" rid="disp-formula1-1740774513478229">Equation (1)</xref> is possible for certain situations [<xref ref-type="bibr" rid="bibr3-1740774513478229">3</xref>,<xref ref-type="bibr" rid="bibr7-1740774513478229">7</xref>]. However, both <inline-formula id="inline-formula4-1740774513478229"><mml:math display="inline" id="math5-1740774513478229"><mml:mrow><mml:mtext>P</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mtext>study</mml:mtext><mml:mspace width="0.25em"/><mml:mtext>success</mml:mtext><mml:mo stretchy="false">|</mml:mo><mml:mi>Δ</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> and <inline-formula id="inline-formula5-1740774513478229"><mml:math display="inline" id="math6-1740774513478229"><mml:mrow><mml:mtext>P</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mi>Δ</mml:mi><mml:mo stretchy="false">|</mml:mo><mml:mtext>data</mml:mtext><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> could become complex, and without closed forms; thus, the integral in <xref ref-type="disp-formula" rid="disp-formula1-1740774513478229">Equation (1)</xref> is not always easy or possible to calculate. We therefore need to turn to trial simulation to estimate PrSS [<xref ref-type="bibr" rid="bibr3-1740774513478229">3</xref>,<xref ref-type="bibr" rid="bibr7-1740774513478229">7</xref>]. For the simulation, we follow the following two steps:</p>
<list id="list1-1740774513478229" list-type="order">
<list-item>
<p>Use Bayesian modeling to synthesize available data and derive <inline-formula id="inline-formula6-1740774513478229"><mml:math display="inline" id="math7-1740774513478229"><mml:mrow><mml:mi>P</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>Δ</mml:mi><mml:mo stretchy="false">|</mml:mo><mml:mtext>data</mml:mtext><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>. As demonstrated later, data often come from different studies and in different forms, requiring creative modeling considering various scenarios.</p>
</list-item>
<list-item>
<p>Estimate PrSS using trial simulation. This is done as follows:</p>
<list id="list2-1740774513478229" list-type="alpha-lower">
<list-item>
<p>Draw a Δ from <inline-formula id="inline-formula7-1740774513478229"><mml:math display="inline" id="math8-1740774513478229"><mml:mrow><mml:mi>P</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>Δ</mml:mi><mml:mo stretchy="false">|</mml:mo><mml:mtext>data</mml:mtext><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula></p>
</list-item>
<list-item>
<p>Simulate a study according to the study design, the Δ drawn in (a), and the expected study execution parameters such as enrollment and drop-out rates</p>
</list-item>
<list-item>
<p>Analyze the simulated study according to the prespecified plan and record whether the study is successful (achieves a significant p-value)</p>
</list-item>
<list-item>
<p>Repeat a–c 10,000 times and calculate the proportion of successful studies. The proportion estimates PrSS defined in <xref ref-type="disp-formula" rid="disp-formula1-1740774513478229">Equation (1)</xref>.</p>
</list-item>
</list>
</list-item>
</list>
</sec>
<sec id="section9-1740774513478229">
<title>Applications</title>
<p>At Eli Lilly, we have applied the procedure described in the Methods section to evaluate PrSS for a number of studies. This has helped improve study designs and inform decision making. In this section, we will share three applications, and each of them provides some unique learning experience. Since the specific information is still confidential, the problem and solution will be described in general terms, and some specific information will be altered or disguised.</p>
<sec id="section10-1740774513478229">
<title>Example 1</title>
<p>We start with a simple example where the analytical and simulation approach is quite straightforward, yet when implemented, it provides very useful information for decision making.</p>
<p>For this example, a randomized ph3 study in planning compares an experimental regimen (E) with a control regimen (C) in a solid tumor. Primary endpoint is the overall survival (OS) time from randomization. Data from a preceding randomized phase II (ph2) study are available. The estimated hazard ratio (HR) from the ph2 study is ~0.8, and the study team designed the new study with a 90% power at this point estimate, which calls for 878 events based on 1-sided log rank test with an alpha of 2.5%. The planned enrollment is 1200 patients. Certainly, in this example, the available data were used to inform the design for the ph3 study. However, only the point estimate of the HR was used, and the variability was not taken into consideration.</p>
<p>For this simple example, the closed form of the PrSS in <xref ref-type="disp-formula" rid="disp-formula1-1740774513478229">Equation (1)</xref> is available based on the normal approximation of the log HR [<xref ref-type="bibr" rid="bibr7-1740774513478229">7</xref>] and is reproduced here</p>
<p>
<disp-formula id="disp-formula2-1740774513478229">
<label>(2)</label>
<mml:math display="block" id="math9-1740774513478229">
<mml:mrow>
<mml:mtext>PrSS</mml:mtext>
<mml:mo>=</mml:mo>
<mml:mtext>Φ</mml:mtext>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mfrac>
<mml:mrow>
<mml:mo>−</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>96</mml:mn>
<mml:msqrt>
<mml:mrow>
<mml:mfrac>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>r</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>3</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>r</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>3</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>3</mml:mn>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:mfrac>
</mml:mrow>
</mml:msqrt>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>θ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msub>
</mml:mrow>
<mml:mrow>
<mml:msqrt>
<mml:mrow>
<mml:mfrac>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>r</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>3</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>r</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>3</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>3</mml:mn>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:mfrac>
<mml:mo>+</mml:mo>
<mml:mfrac>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>r</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>r</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:mfrac>
</mml:mrow>
</mml:msqrt>
</mml:mrow>
</mml:mfrac>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula2-1740774513478229" xlink:href="10.1177_1740774513478229-eq2.tif"/>
</disp-formula>
</p>
<p>where <inline-formula id="inline-formula8-1740774513478229"><mml:math display="inline" id="math10-1740774513478229"><mml:mrow><mml:mtext>Φ</mml:mtext></mml:mrow></mml:math></inline-formula> is the standard normal cumulative distribution function; <italic>r</italic><sub>2</sub> and <italic>r</italic><sub>3</sub> are the randomization ratios for the ph2 and ph3 studies, respectively; <italic>d</italic><sub>2</sub> and <italic>d</italic><sub>3</sub> are the number of events from the two studies; and <inline-formula id="inline-formula9-1740774513478229"><mml:math display="inline" id="math11-1740774513478229"><mml:mrow><mml:msub><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> is the observed HR from the ph2 study. Using <xref ref-type="disp-formula" rid="disp-formula2-1740774513478229">Equation (2)</xref>, the PrSS for the planned ph3 study is about 66%, which is substantially lower than the desired power (90%). The difference lies in the fact that the PrSS accounts for the variability while the traditional power calculation assumes the point estimate is a fixed constant. Typically, the PrSS is lower than the power evaluated at the prior mean, provided the power is above 50% [<xref ref-type="bibr" rid="bibr6-1740774513478229">6</xref>].</p>
<p>We also evaluated the PrSS using the simulation approach in order to (1) understand other operating characteristics such as duration of the study and observed treatment effect and (2) evaluate more complicated designs such as adding interim analyses. First, we used the following simple model to fit the ph2 data and derive <inline-formula id="inline-formula10-1740774513478229"><mml:math display="inline" id="math12-1740774513478229"><mml:mrow><mml:mtext>P</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mi>Δ</mml:mi><mml:mo stretchy="false">|</mml:mo><mml:mtext>data</mml:mtext><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula></p>
<p>
<disp-formula id="disp-formula3-1740774513478229">
<label>(3)</label>
<mml:math display="block" id="math13-1740774513478229">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>T</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mspace width="0.25em"/>
<mml:mo>~</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mi>Exp</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>λ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>;</mml:mo>
<mml:mspace width="0.25em"/>
<mml:msub>
<mml:mrow>
<mml:mi>λ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mspace width="0.25em"/>
<mml:mo>~</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mi>Gamma</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>0001</mml:mn>
<mml:mo>,</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>0001</mml:mn>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula3-1740774513478229" xlink:href="10.1177_1740774513478229-eq3.tif"/>
</disp-formula>
</p>
<p>where <italic>i</italic> = E or C is the treatment arm indicator, and <italic>T<sub>i</sub></italic> denotes the survival time for arm <italic>i</italic> and is assumed to follow an exponential distribution with a constant hazard <inline-formula id="inline-formula11-1740774513478229"><mml:math display="inline" id="math14-1740774513478229"><mml:mrow><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>. We used a noninformative prior, <italic>Gamma</italic> (0.0001, 0.0001), for the hazards. We fitted model (3) to the ph2 data and obtained the posterior distributions of the <italic>λ</italic>s. Those posteriors became the prior distributions of the treatment effect when we evaluated PrSS for the new study. We then conducted trial simulation to evaluate PrSS for the pivotal ph3 study, following the procedure described in the Methods section earlier. Of the 10,000 simulated studies, 6673 have a p-value less than 2.5% at the final analysis, and therefore, the PrSS for the ph3 study is approximately 67%, virtually the same as the analytical result. We note that the same simulation approach was discussed in Ref. [<xref ref-type="bibr" rid="bibr7-1740774513478229">7</xref>], where the hazard <inline-formula id="inline-formula12-1740774513478229"><mml:math display="inline" id="math15-1740774513478229"><mml:mrow><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> was assumed to follow an inverse Gamma distribution. In the setting of this example, both models produced essentially the same results.</p>
<p>In addition to PrSS, other characteristics of the study design were obtained from the simulation. For instance, the distributions of the study duration and estimated treatment effect for the ph3 trial were derived based on the 10,000 simulated studies. The mean of the study duration was ~41 months, and the mean of median survival difference between E and C was 2.7 months for all the 10,000 studies and, more relevantly, 4.2 months for the 6673 successful studies. As expected, the improvement was larger for the positive studies, though it is also created in part by the selection bias of reporting only positive results.</p>
<p>Given the relatively high PrSS and the sample size, one would expect that adding an interim analysis could enable an early claim of efficacy, therefore saving time of the ph3 development. We therefore proposed adding an interim analysis and used simulation to quantify the potential time saving. One of the alternative designs we considered had an interim analysis at 75% of the total events with the O’Brien–Fleming alpha-spending rule: 1-sided alpha of 0.01 at interim and 0.022 at final. The maximum sample size was maintained at 1200 patients to meet the budgetary constraint. With the interim analysis, the required maximum number of events went up slightly to 894. We simulated 10,000 studies based on this new design. As expected, the new design maintains the PrSS (about 67%) and cuts the average study duration by 6 months as the study has ~60% chance to stop at the interim. <xref ref-type="table" rid="table1-1740774513478229">Table 1</xref> summarizes the simulation outcome.</p>
<table-wrap id="table1-1740774513478229" position="float">
<label>Table 1.</label>
<caption>
<p>Simulation outcome for an alternative design for Example 1</p>
</caption>
<graphic alternate-form-of="table1-1740774513478229" xlink:href="10.1177_1740774513478229-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="left"/>
<col align="char" char="."/>
</colgroup>
<tbody>
<tr>
<td align="left" colspan="5">Total number of simulated trials: 10,000</td>
</tr>
<tr>
<td>Interim p-value</td>
<td>&lt; 0.01</td>
<td/>
<td>≥ 0.01</td>
<td/>
</tr>
<tr>
<td>Number of trials</td>
<td>5,911</td>
<td/>
<td>4089</td>
<td/>
</tr>
<tr>
<td>Final p-value</td>
<td>N/A</td>
<td>&lt;0.022</td>
<td/>
<td>≥ 0.022</td>
</tr>
<tr>
<td>Number of trials</td>
<td>N/A</td>
<td>772</td>
<td/>
<td>3317</td>
</tr>
<tr>
<td>Average study</td>
<td>31.3 months</td>
<td/>
<td>42.4 months</td>
<td/>
</tr>
</tbody>
</table>
</table-wrap>
<p>These explorations helped the team realize that the success rate was lower than they had initially thought, gave options for improving the design, and helped them rethink whether to invest in this study, considering options for investing in other indications and molecules. The primary lessons from this evaluation are that even in this simple and ideal situation, there is a great deal of opportunity for statisticians to take the lead in (1) utilizing all the information available to provide a more realistic ph3 success rate, (2) making various options available to the team so that they can pick the option that best suits the business needs, and (3) helping statistics and statisticians become an integral part of decision making in the drug development process.</p>
</sec>
<sec id="section11-1740774513478229">
<title>Example 2</title>
<p>In this example, we present our work on a ph3 study that is more complicated than Example 1. Here, we had data from two single-arm studies (with slightly different dosing) of an experimental therapy (E), and there was much historical data available on standard of care therapy (C). However, no data were available on the combination of E and C (E + C). Based on these data, the team decided to pursue a ph3 study comparing E + C versus C. Considering the payer requirements and marketing needs, the study was designed assuming E + C can prolong the median survival by 4 months (33% improvement), needing 450 events (sample size of 600) for a 86% power. In our experience, this is commonly done, and statisticians generally go along with the approach. In this case, we decided to take a creative approach to build models and simulations fully utilizing the existing data.</p>
<p>Our primary challenge was to develop models to project how E and C would work in combination. The first step was to derive the survival distributions for the single agents using relevant data. We identified six studies on C from the literature. We then used a meta-analytical approach to derive the survival distribution from the six studies. Similarly, we obtained the distribution for the single agent E using the two internal studies. Specifically, the following model was used to fit the data</p>
<p>
<disp-formula id="disp-formula4-1740774513478229">
<mml:math display="block" id="math16-1740774513478229">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>T</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>is</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mspace width="0.25em"/>
<mml:mo>~</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mi>Exponential</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>λ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>is</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula4-1740774513478229" xlink:href="10.1177_1740774513478229-eq4.tif"/>
</disp-formula>
</p>
<p>
<disp-formula id="disp-formula5-1740774513478229">
<mml:math display="block" id="math17-1740774513478229">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>λ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>is</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mspace width="0.25em"/>
<mml:mo>~</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mi>Gamma</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>,</mml:mo>
<mml:mspace width="0.25em"/>
<mml:msub>
<mml:mrow>
<mml:mi>β</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula5-1740774513478229" xlink:href="10.1177_1740774513478229-eq5.tif"/>
</disp-formula>
</p>
<p>
<disp-formula id="disp-formula6-1740774513478229">
<label>(4)</label>
<mml:math display="block" id="math18-1740774513478229">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>,</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>β</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mspace width="0.25em"/>
<mml:mo>~</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mi>Gamma</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>0001</mml:mn>
<mml:mo>,</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>0001</mml:mn>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula6-1740774513478229" xlink:href="10.1177_1740774513478229-eq6.tif"/>
</disp-formula>
</p>
<p>where <italic>i</italic> denotes the treatment, <italic>s</italic> denotes the study within treatment <italic>i</italic> (for <italic>i</italic> = E, <italic>s</italic> = 1, 2; for <italic>i</italic> = C, <italic>s</italic> = 1,2, …, 6). <inline-formula id="inline-formula13-1740774513478229"><mml:math display="inline" id="math19-1740774513478229"><mml:mrow><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>is</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> is the survival time for study <italic>s</italic> of treatment <italic>i</italic>, assumed to follow an exponential distribution with the hazard of <inline-formula id="inline-formula14-1740774513478229"><mml:math display="inline" id="math20-1740774513478229"><mml:mrow><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mi>is</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>. The hazards from different studies of the same treatment <italic>i</italic> are assumed to follow <inline-formula id="inline-formula15-1740774513478229"><mml:math display="inline" id="math21-1740774513478229"><mml:mrow><mml:mi>Gamma</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>α</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>, and we put noninformative priors on <inline-formula id="inline-formula16-1740774513478229"><mml:math display="inline" id="math22-1740774513478229"><mml:mrow><mml:msub><mml:mrow><mml:mi>α</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula id="inline-formula17-1740774513478229"><mml:math display="inline" id="math23-1740774513478229"><mml:mrow><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>, leading to a Bayesian hierarchical model that is commonly used to synthesize evidence from multiple studies [<xref ref-type="bibr" rid="bibr6-1740774513478229">6</xref>].</p>
<p>Model (4) was fitted separately for E and C, and posterior distributions of the parameters were derived. We then simulated the survival data for the control arm of the ph3 study based on the posterior distribution of the hazard, <inline-formula id="inline-formula18-1740774513478229"><mml:math display="inline" id="math24-1740774513478229"><mml:mrow><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>.</p>
<p>Since there are no data available for E + C, we considered several scenarios on how E and C might work together. We eventually settled on two cases, a pessimistic scenario and a more optimistic scenario, after exploring a number of scenarios based on discussions among the team.</p>
<p>For the pessimistic scenario, we assumed that the survival time of a patient treated with E + C would be the longer of the survival times associated with the two single agents, that is, the two treatments provide independent survival hazards, and the benefit of the combination is the minimum of hazards from the individual treatments. While we call this the pessimistic scenario, theoretically, it is not the most pessimistic because it still assumes that there is no antagonism between E and C. For this study, this is a more realistic scenario than assuming antagonism as preclinical models suggest antagonism is unlikely. In fact, the hope is that a combination is better based on the preclinical data. Hence, we assume that the survival of the better of the two agents will remain while the other one provides no additional benefit.</p>
<p>For the optimistic scenario, we assumed that the benefit of the combination treatment, relative to no treatment, is the product of the relative benefits of each single agent alone, which essentially implies the following relationship in terms of HRs</p>
<p>
<disp-formula id="disp-formula7-1740774513478229">
<mml:math display="block" id="math25-1740774513478229">
<mml:mrow>
<mml:mfrac>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>λ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>E</mml:mi>
<mml:mo>+</mml:mo>
<mml:mi>C</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>λ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>U</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:mfrac>
<mml:mo>=</mml:mo>
<mml:mfrac>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>λ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>E</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>λ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>U</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:mfrac>
<mml:mo>×</mml:mo>
<mml:mfrac>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>λ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>C</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>λ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>U</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:mfrac>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula7-1740774513478229" xlink:href="10.1177_1740774513478229-eq7.tif"/>
</disp-formula>
</p>
<p>where <inline-formula id="inline-formula19-1740774513478229"><mml:math display="inline" id="math26-1740774513478229"><mml:mrow><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mi>E</mml:mi><mml:mo>+</mml:mo><mml:mi>C</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>, <inline-formula id="inline-formula20-1740774513478229"><mml:math display="inline" id="math27-1740774513478229"><mml:mrow><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mi>E</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>, <inline-formula id="inline-formula21-1740774513478229"><mml:math display="inline" id="math28-1740774513478229"><mml:mrow><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>, and <inline-formula id="inline-formula22-1740774513478229"><mml:math display="inline" id="math29-1740774513478229"><mml:mrow><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mi>U</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> are the hazard of death for patients treated with the combination treatment, single agent E, single agent C, and untreated patients, respectively. This is equivalent to strict additivity of drug effect on the log scale (i.e., no interaction between E and C). Just as the pessimistic scenario does not assume antagonism, this does not assume synergy between the two treatments and hence is not the most optimistic scenario. As none of the studies evaluated included a placebo arm, which is still common in oncology, we estimated the hazard for untreated patients from the poorest study estimate for C. It was assumed that this represented a patient sample in which therapy C had little or no activity. It can be noted that this will provide a conservative estimate of the HRs as long as C did not inflict harm in any patient sample.</p>
<p>Combining the posterior distribution from <xref ref-type="disp-formula" rid="disp-formula4-1740774513478229">Equation (4)</xref> using the assumptions on how E and C work together, we simulated the survival time for the control arm and the combination arm for the ph3 study and calculated the PrSS for the designed ph3 study. <xref ref-type="table" rid="table2-1740774513478229">Table 2</xref> summarizes PrSS of the study for different sample sizes with an assumed censoring rate of 20%.</p>
<table-wrap id="table2-1740774513478229" position="float">
<label>Table 2.</label>
<caption>
<p>PrSS for different sample sizes and assumptions for Example 2</p>
</caption>
<graphic alternate-form-of="table2-1740774513478229" xlink:href="10.1177_1740774513478229-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Sample size</th>
<th align="center">200</th>
<th align="center">400</th>
<th align="center">600</th>
<th align="center">800</th>
<th align="center">1,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>PrSS under pessimistic assumption</td>
<td>33%</td>
<td>42%</td>
<td>45%</td>
<td>48%</td>
<td>49%</td>
</tr>
<tr>
<td>PrSS under optimistic assumption</td>
<td>55%</td>
<td>62%</td>
<td>65%</td>
<td>67%</td>
<td>68%</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1740774513478229">
<p>PrSS: probability of study success.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>It is evident that the PrSS would be between 45% and 65% for a 600-patient study, suggesting that current data provide only minimal support for the alternative hypothesis. Under the pessimistic scenario, PrSS does not increase much with increased sample size because the single-agent treatment effects were similar enough that the data suggest the combination would not provide benefit in the absence of additivity. Also, it became clear that under the optimistic scenario, even a study almost twice as large would not have a PrSS over 70%. This is because the sample sizes for the ph2 studies of the new treatment E are small, and therefore, the distribution of treatment effect has a large variance, leading to a large probability mass for no or harmful treatment effect. When this happens, increasing the sample size will not improve PrSS much because the power function is bounded at a fixed value (i.e., the significance level) under no or harmful treatment effect regardless of the sample size [<xref ref-type="bibr" rid="bibr7-1740774513478229">7</xref>]. It can be seen that it is difficult for limited ph2 data to support a large ph3 trial. Therefore, clinical plans should include ph2 studies of sufficient size and/or number to provide adequate prior evidence of clinically meaningful efficacy.</p>
<p>Because choosing a sample size larger than 600 for this particular study was not supported by the available evidence, we investigated adding futility analyses to discharge the risk associated with limited knowledge of the combination and provided detailed analyses of PrSS, discussing chances of false positive and false negative. This provided valuable information to the study team and helped decide whether and how we should move forward with the ph3 study or to conduct a randomized ph2 study instead.</p>
<p>This situation was more complicated than the first example and required greater statistical thinking and afforded an opportunity to provide greater leadership to influence the team on their thinking and the development strategy.</p>
</sec>
<sec id="section12-1740774513478229">
<title>Example 3</title>
<p>In oncology, though OS is typically the primary endpoint for ph3 studies, correlated or surrogate endpoints such as the progression-free survival (PFS; defined as the duration from randomization to the earlier of tumor progression or death) are commonly used as the primary endpoint in ph2. This is especially true for less-aggressive cancers associated with relatively long OS so as to keep the size and duration of ph2 studies to a reasonable level. In this example, we will discuss how to evaluate PrSS when different endpoints are used between phases and little information is available from ph2 study on the ph3 endpoint.</p>
<p>We had a randomized ph2 study to compare E + C versus C in metastatic breast cancer (MBC). The primary endpoint was PFS, and only a few OS events were observed at the study completion. Given the changing regulatory environment on MBC, we needed to evaluate how likely we would demonstrate OS benefit for a ph3 study. Since the OS data from the ph2 are sparse, we decided to only use the PFS data from the ph2 and leveraged external data to link the treatment effect on PFS and OS in MBC and used that linkage to estimate the PrSS for ph3.</p>
<p>A major meta-analysis for MBC was published in 2008 [<xref ref-type="bibr" rid="bibr8-1740774513478229">8</xref>], which included 67 MBC studies with more than 17,000 patients in total. The analysis aimed to quantify the relationship between the treatment effects, in terms of HR, on PFS and OS for MBC. Using the same data attached in the article, we fitted the following regression model</p>
<p>
<disp-formula id="disp-formula8-1740774513478229">
<mml:math display="block" id="math30-1740774513478229">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>θ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mtext>OS</mml:mtext>
</mml:mrow>
</mml:msub>
<mml:mspace width="0.25em"/>
<mml:mo>~</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mi>N</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>β</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>β</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:msub>
<mml:mrow>
<mml:mi>θ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mtext>PFS</mml:mtext>
</mml:mrow>
</mml:msub>
<mml:mo>,</mml:mo>
<mml:mspace width="0.25em"/>
<mml:msup>
<mml:mrow>
<mml:mi>σ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msup>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula8-1740774513478229" xlink:href="10.1177_1740774513478229-eq8.tif"/>
</disp-formula>
</p>
<p>
<disp-formula id="disp-formula9-1740774513478229">
<mml:math display="block" id="math31-1740774513478229">
<mml:mrow>
<mml:mi>π</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>β</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>,</mml:mo>
<mml:mspace width="0.25em"/>
<mml:msub>
<mml:mrow>
<mml:mi>β</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>∝</mml:mo>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula9-1740774513478229" xlink:href="10.1177_1740774513478229-eq9.tif"/>
</disp-formula>
</p>
<p>
<disp-formula id="disp-formula10-1740774513478229">
<label>(5)</label>
<mml:math display="block" id="math32-1740774513478229">
<mml:mrow>
<mml:mi>σ</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mo>~</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mi>Gamma</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>a</mml:mi>
<mml:mo>,</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mi>b</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula10-1740774513478229" xlink:href="10.1177_1740774513478229-eq10.tif"/>
</disp-formula>
</p>
<p>where <inline-formula id="inline-formula23-1740774513478229"><mml:math display="inline" id="math33-1740774513478229"><mml:mrow><mml:msub><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mtext>OS</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula id="inline-formula24-1740774513478229"><mml:math display="inline" id="math34-1740774513478229"><mml:mrow><mml:msub><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mtext>PFS</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> are the log HR for OS and PFS, respectively; <italic>β</italic><sub>0</sub> and <italic>β</italic><sub>1</sub> are the coefficients of interest; <italic>σ</italic> is the scale parameter; and <italic>a</italic> and <italic>b</italic> are chosen to give a diffuse prior for <italic>σ</italic>. The linear model in <xref ref-type="disp-formula" rid="disp-formula5-1740774513478229">Equation (5)</xref> was justified by a clear linear trend between the log HRs on a scatter plot. Fitting the model in <xref ref-type="disp-formula" rid="disp-formula5-1740774513478229">Equation (5)</xref> to the 67 pairs of log HRs in Ref. [<xref ref-type="bibr" rid="bibr8-1740774513478229">8</xref>] gave us the posterior distributions for <italic>β</italic><sub>0</sub>, <italic>β</italic><sub>1</sub>, and <italic>σ</italic>.</p>
<p>We then obtained the posterior distribution of the log HR for PFS, <inline-formula id="inline-formula25-1740774513478229"><mml:math display="inline" id="math35-1740774513478229"><mml:mrow><mml:msub><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mtext>PFS</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>, from our ph2 study, using similar modeling as in Example 1. Then a posterior sample of HR for OS was generated by repeating the following steps:</p>
<list id="list3-1740774513478229" list-type="order">
<list-item>
<p>Draw a <inline-formula id="inline-formula26-1740774513478229"><mml:math display="inline" id="math36-1740774513478229"><mml:mrow><mml:msub><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mtext>PFS</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> from the posterior distribution derived from the ph2 data</p>
</list-item>
<list-item>
<p>Draw a set of <italic>β</italic><sub>0</sub>, <italic>β</italic><sub>1</sub>, and <italic>σ</italic> from the posterior distributions derived from fitting <xref ref-type="disp-formula" rid="disp-formula5-1740774513478229">Equation (5)</xref> to the data in Ref. [<xref ref-type="bibr" rid="bibr8-1740774513478229">8</xref>]</p>
</list-item>
<list-item>
<p>Generate a <inline-formula id="inline-formula27-1740774513478229"><mml:math display="inline" id="math37-1740774513478229"><mml:mrow><mml:msub><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mtext>OS</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> from <inline-formula id="inline-formula28-1740774513478229"><mml:math display="inline" id="math38-1740774513478229"><mml:mrow><mml:mi>N</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mtext>PFS</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula></p>
</list-item>
</list>
<p>Once the posterior sample of the log HR of OS was generated, we followed the same simulation algorithm in the Methods section to estimate the PrSS of the ph3 study. For our example, the PFS HR from the ph2 study was 0.65 based on 120 PFS events and the estimated probability of hitting a significant p-value in the ph3 study was about 54%. Of note, the ph3 study plans to achieve 720 OS events to ensure an 85% power at a HR of 0.8. These analysis and discussions aided the team and the governance body to decide whether we should pursue the ph3 study with OS as the primary endpoint and how the study should be designed.</p>
<p>In Example 1, we accounted for the uncertainty of the ph2 treatment effect size estimate. In this example, we extended this by accounting for the uncertainty of the ph2 treatment effect size estimate while also accounting for the uncertainty of the relationship between the ph2 endpoint (PFS) and the ph3 endpoint (OS), as reflected by the published meta-analysis. The approach can be applied to situations where relevant meta-analysis is available to link the treatment effects on PFS and OS. Such meta-analysis has been done for major tumor types, such as lung cancer, breast cancer, and colon cancer [<xref ref-type="bibr" rid="bibr8-1740774513478229">8</xref>,<xref ref-type="bibr" rid="bibr9-1740774513478229">9</xref>].</p>
<p>Another method that we have used for different endpoints is based on the surrogate threshold effect [<xref ref-type="bibr" rid="bibr10-1740774513478229">10</xref>]. For example, a recent research [<xref ref-type="bibr" rid="bibr11-1740774513478229">11</xref>] indicated that for non-small-cell lung cancer, the surrogate threshold effect for PFS is a HR of 0.7, meaning that a reduction of at least 30% in the risk of PFS would predict a statistically significant survival effect [<xref ref-type="bibr" rid="bibr12-1740774513478229">12</xref>]. Using this work, we can solve the challenge of different endpoints by estimating <inline-formula id="inline-formula29-1740774513478229"><mml:math display="inline" id="math39-1740774513478229"><mml:mrow><mml:mtext>Pr</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mtext>ph</mml:mtext><mml:mn>3</mml:mn><mml:mspace width="0.25em"/><mml:mtext>PFS</mml:mtext><mml:mspace width="0.25em"/><mml:mtext>HR</mml:mtext><mml:mo>&lt;</mml:mo><mml:mn>0</mml:mn><mml:mo>.</mml:mo><mml:mn>7</mml:mn><mml:mo>|</mml:mo></mml:mrow><mml:mtext>ph</mml:mtext><mml:mn>2</mml:mn><mml:mspace width="0.25em"/><mml:mtext>PFS</mml:mtext><mml:mspace width="0.25em"/><mml:mtext>data</mml:mtext><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>. We applied this idea to one of our lung cancer programs.</p>
</sec>
</sec>
<sec id="section13-1740774513478229" sec-type="discussion">
<title>Discussion</title>
<p>In oncology alone, the industry pipeline carries more than 850 compounds in development across all the stages [<xref ref-type="bibr" rid="bibr13-1740774513478229">13</xref>]. While this affords a phenomenal opportunity, it also highlights a need to optimize resources (funding, human resources, and patient resources) needed to develop those compounds and bring them to patients. Therefore, it is of critical importance for sponsors to have quantitative decision tools to appropriately prioritize and invest in their compounds and studies. Even where resources are sufficient, it is important to utilize analytical or statistical tools to optimize clinical planning that lead to better decision making.</p>
<p>Many factors need to be considered when prioritizing, such as medical needs, regulatory requirements, marketing potential, and so on. A primary factor that determines whether any investment should be made is whether one expects the ph3 study to succeed with high probability or not. While this is important, it is well known that the traditional statistical power cannot characterize PrSS reliably as it is derived from an assumed treatment effect and does not account for variability or uncertainty. As argued by a number of authors [<xref ref-type="bibr" rid="bibr3-1740774513478229">3</xref>,<xref ref-type="bibr" rid="bibr4-1740774513478229">4</xref>,<xref ref-type="bibr" rid="bibr7-1740774513478229">7</xref>], PrSS defined in <xref ref-type="disp-formula" rid="disp-formula1-1740774513478229">Equation (1)</xref> better quantifies the likelihood of study success. In this article, we illustrated how to evaluate PrSS via trial simulation because analytical calculation of <xref ref-type="disp-formula" rid="disp-formula1-1740774513478229">Equation (1)</xref> is often not feasible. We demonstrated application of this idea through three real examples. Our approach has informed internal decision makers and study teams in prioritizing those studies, choosing study designs, and constructing the clinical plans.</p>
<p>We illustrated that PrSS can help optimize individual study designs. For example, if the PrSS is high, it makes sense to employ an aggressive study design such as allowing stopping early for efficacy; on the other hand, futility interim analysis may be needed if the available data indicate a low PrSS. A related point worth mentioning is that, for certain situations where there is little information or weak support for the alternative hypothesis, increasing sample size has little impact on PrSS, as demonstrated in Example 2. This may help a sponsor to decide whether additional studies or incorporating an interim futility analysis would be appropriate, in light of the available evidence. We note that because PrSS defined in <xref ref-type="disp-formula" rid="disp-formula1-1740774513478229">Equation (1)</xref> is based on available data, a low PrSS does not necessarily mean that an investigational treatment is not promising; it could be due to the fact that data on the new treatment are sparse, leading to a disperse <inline-formula id="inline-formula30-1740774513478229"><mml:math display="inline" id="math40-1740774513478229"><mml:mrow><mml:mtext>P</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mi>Δ</mml:mi><mml:mo stretchy="false">|</mml:mo><mml:mtext>data</mml:mtext><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> and consequently a low PrSS. From this perspective, PrSS evaluation could inform how we should size the ph2 studies so that <inline-formula id="inline-formula31-1740774513478229"><mml:math display="inline" id="math41-1740774513478229"><mml:mrow><mml:mi>P</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>Δ</mml:mi><mml:mo stretchy="false">|</mml:mo><mml:mtext>data</mml:mtext><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> is tight enough to generate a high PrSS for the subsequent ph3 study. More importantly, how do we optimally allocate limited resources between a ph2 study and the subsequent ph3 study to maximize the overall chance of success? This important question was discussed by some authors [<xref ref-type="bibr" rid="bibr6-1740774513478229">6</xref>,<xref ref-type="bibr" rid="bibr14-1740774513478229">14</xref>] and certainly needs more work.</p>
<p>In oncology, OS is typically the primary endpoint for the confirmatory pivotal studies, but certain correlated or assumed surrogate endpoints such as PFS are often used as the primary endpoint in ph2 studies. If the OS data are not available or too sparse from ph2, external data can be used to link the treatment effects on the different endpoints. In Example 3, we demonstrated how this could be done for a MBC study where OS data were really sparse. An alternative is to leverage on the surrogate threshold effect, if such as threshold is established in the target tumor type. When a meaningful amount of OS data are also available (though less mature than PFS data), both PFS and OS data could be used to enhance the analysis. One could use the multivariate approach in Ref. [<xref ref-type="bibr" rid="bibr12-1740774513478229">12</xref>], or jointly model OS and PFS and then use the improved OS result to predict PrSS for the ph3 [<xref ref-type="bibr" rid="bibr15-1740774513478229">15</xref>]. For many situations, analytical prediction of OS effect based on the effect on an surrogate endpoint such as PFS is probably the best we could do due to practical reasons. However, we do want to point out that lack of adequate study of the investigational regimen in ph2 is a major reason for the high ph3 failure rate. When practically feasible, we should collect adequate OS data in ph2 if it is going to be the primary endpoint for ph3.</p>
<p>As demonstrated in the examples, the evaluation of PrSS for a pivotal study is based on the ph2 data and historical knowledge when available. Therefore, it is of critical importance to ensure that the data used are relevant to the new study that is under evaluation. Caution should be exercised when extrapolating any study results to a new study. It takes cross-functional efforts to select appropriate studies to ensure their key characteristics (such as treatment regimens, patient population, supportive care) are similar to those of the new study. If justified, discounting the treatment effect observed in the available data should also be considered [<xref ref-type="bibr" rid="bibr14-1740774513478229">14</xref>]. Such effort should be made before the PrSS analysis is done to prevent selection bias. If the assumption of the exchangeable treatment effect between the ph2 and the ph3 studies cannot be reasonably met, the PrSS analysis has no or little value.</p>
<p>In conclusion, we think PrSS based on available data is a useful measure to quantify the likelihood of study success. Based on our experience, evaluating PrSS can bring great insights into prioritizing studies, improving study designs, and constructing clinical plans, which ultimately leads to better decision making and more efficient drug development. Therefore, it should be considered and done routinely when applicable. The procedure based on trial simulation is general and can be applied broadly.</p>
</sec>
</body>
<back>
<ack>
<p>The authors are grateful to the editor, associate editor, and referees for reviewing this article that led to the improved final version. The authors also wish to acknowledge the advice and insight of Luping Zhao.</p>
</ack>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This work is entirely funded by Eli Lilly and Company.</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of interest</label>
<p>None declared.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1740774513478229">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>DiMasi</surname><given-names>JA</given-names></name>
<name><surname>Feldman</surname><given-names>L</given-names></name>
<name><surname>Seckler</surname><given-names>A</given-names></name>
<name><surname>Wilson</surname><given-names>A</given-names></name>
</person-group>. <article-title>Trends in risks associated with new drug development: Success rates for investigational drugs</article-title>. <source>Clin Pharmacol Ther</source> <year>2010</year>; <volume>87</volume>: <fpage>272</fpage>–<lpage>77</lpage>.</citation>
</ref>
<ref id="bibr2-1740774513478229">
<label>2.</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name><surname>Sutter</surname><given-names>S</given-names></name>
<name><surname>Lamotta</surname><given-names>L</given-names></name>
</person-group>. <article-title>Cancer drugs have worst phase III track record</article-title>. <source>Intern Med News</source> <year>2011</year>. Available at: <ext-link ext-link-type="uri" xlink:href="http:///www.ehospitalistnews.comindex.php?id=779&amp;tx_ttnews%5Btt_news%5D=41774&amp;cHash=513e57ba8d489ddb10a0f95554b7f284">/www.ehospitalistnews.comindex.php?id=779&amp;tx_ttnews%5Btt_news%5D=41774&amp;cHash=513e57ba8d489ddb10a0f95554b7f284</ext-link></citation>
</ref>
<ref id="bibr3-1740774513478229">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Hagan</surname><given-names>A</given-names></name>
<name><surname>Stevens</surname><given-names>J</given-names></name>
<name><surname>Campbell</surname><given-names>MJ</given-names></name>
</person-group>. <article-title>Assurance in clinical trial design</article-title>. <source>Pharm Stat</source> <year>2005</year>; <volume>4</volume>: <fpage>187</fpage>–<lpage>201</lpage>.</citation>
</ref>
<ref id="bibr4-1740774513478229">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chuang-Stein</surname><given-names>C</given-names></name>
</person-group>. <article-title>Sample size and the probability of a successful trial</article-title>. <source>Pharm Stat</source> <year>2006</year>; <volume>5</volume>: <fpage>305</fpage>–<lpage>09</lpage>.</citation>
</ref>
<ref id="bibr5-1740774513478229">
<label>5.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Dmitrienko</surname><given-names>A</given-names></name>
<name><surname>Molenberghs</surname><given-names>G</given-names></name>
<name><surname>Chuang-Stein</surname><given-names>C</given-names></name>
<name><surname>Offen</surname><given-names>W</given-names></name>
</person-group>. <source>Analysis of Clinical Trials Using SAS: A Practical Guide</source>. <publisher-name>SAS Institute Inc</publisher-name>., <publisher-loc>Cary, NC</publisher-loc>, <year>2005</year>, pp. <fpage>248</fpage>–<lpage>61</lpage>.</citation>
</ref>
<ref id="bibr6-1740774513478229">
<label>6.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Spiegelhalter</surname><given-names>DJ</given-names></name>
<name><surname>Abrams</surname><given-names>KR</given-names></name>
<name><surname>Myles</surname><given-names>JP</given-names></name>
</person-group>. <source>Bayesian Approaches to Clinical Trials and Health-Care Evaluation</source>. <publisher-name>Wiley</publisher-name>, <publisher-loc>Chichester</publisher-loc>, <year>2004</year>.</citation>
</ref>
<ref id="bibr7-1740774513478229">
<label>7.</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name><surname>King</surname><given-names>M</given-names></name>
</person-group>. <article-title>Evaluating probability of success in oncology clinical trials</article-title>. In <source>Biopharmaceutical Applied Statistics Symposium</source>, <year>2009</year>. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.bassconference.org/PDFs/Bass%202009%20Martin%20King.pdf">http://www.bassconference.org/PDFs/Bass%202009%20Martin%20King.pdf</ext-link></citation>
</ref>
<ref id="bibr8-1740774513478229">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sherrill</surname><given-names>B</given-names></name>
<name><surname>Amonkar</surname><given-names>M</given-names></name>
<name><surname>Wu</surname><given-names>Y</given-names></name>
<etal/>
</person-group>. <article-title>Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer</article-title>. <source>Br J Cancer</source> <year>2008</year>; <volume>99</volume>: <fpage>1572</fpage>–<lpage>78</lpage>.</citation>
</ref>
<ref id="bibr9-1740774513478229">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Johnson</surname><given-names>KR</given-names></name>
<name><surname>Ringland</surname><given-names>C</given-names></name>
<name><surname>Stokes</surname><given-names>BJ</given-names></name>
<etal/>
</person-group>. <article-title>Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: A meta-analysis</article-title>. <source>Lancet Oncol</source> <year>2006</year>; <volume>7</volume>: <fpage>741</fpage>–<lpage>46</lpage>.</citation>
</ref>
<ref id="bibr10-1740774513478229">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Burzykowski</surname><given-names>T</given-names></name>
<name><surname>Buyse</surname><given-names>M</given-names></name>
</person-group>. <article-title>Surrogate threshold effect: An alternative measure for meta-analytic surrogate endpoint validation</article-title>. <source>Pharm Stat</source> <year>2006</year>; <volume>5</volume>: <fpage>173</fpage>–<lpage>86</lpage>.</citation>
</ref>
<ref id="bibr11-1740774513478229">
<label>11.</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name><surname>Buyse</surname><given-names>ME</given-names></name>
<name><surname>Squifflet</surname><given-names>P</given-names></name>
<name><surname>Laporte</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Prediction of survival benefits from progression-free survival in patients with advanced non small cell lung cancer: Evidence from a pooled analysis of 2,838 patients randomized in 7 trials</article-title>. In <source>American Society of Clinical Oncology Annual Meeting</source>, <year>2008</year>. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=55&amp;abstractID=32835">http://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=55&amp;abstractID=32835</ext-link></citation>
</ref>
<ref id="bibr12-1740774513478229">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hong</surname><given-names>S</given-names></name>
<name><surname>Shi</surname><given-names>L</given-names></name>
</person-group>. <article-title>Predictive power to assist phase 3 go/no go decision based on phase 2 data on a different endpoint</article-title>. <source>Stat Med</source> <year>2011</year>; doi: <pub-id pub-id-type="doi">10.1002/sim.4476</pub-id> (Epub ahead of print).</citation>
</ref>
<ref id="bibr13-1740774513478229">
<label>13.</label>
<citation citation-type="web">
<collab>America’s Pharmaceutical Research Companies</collab>. <article-title>PhRMA report on medicines in development for cancer</article-title>, <year>2011</year>. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.phrma.org/sites/default/files/1000/medicinesindevelopmentcancer2011_0.pdf">http://www.phrma.org/sites/default/files/1000/medicinesindevelopmentcancer2011_0.pdf</ext-link></citation>
</ref>
<ref id="bibr14-1740774513478229">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chuang-Stein</surname><given-names>C</given-names></name>
<name><surname>Kirby</surname><given-names>S</given-names></name>
<name><surname>French</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>A quantitative approach for making go/no-go decisions in drug development</article-title>. <source>Drug Inf J</source> <year>2011</year>; <volume>45</volume>: <fpage>187</fpage>–<lpage>202</lpage>.</citation>
</ref>
<ref id="bibr15-1740774513478229">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fu</surname><given-names>H</given-names></name>
<name><surname>Wang</surname><given-names>Y</given-names></name>
<name><surname>Liu</surname><given-names>J</given-names></name>
<name><surname>Kulkarni</surname><given-names>PM</given-names></name>
<name><surname>Melemed</surname><given-names>A</given-names></name>
</person-group>. <article-title>Joint modeling of progression-free survival and overall survival by a Bayesian normal induced copula estimation model</article-title>. <source>Stat Med</source> <year>2012</year>; doi: <pub-id pub-id-type="doi">10.1002/sim.5487</pub-id> (Epub ahead of print).</citation>
</ref>
</ref-list>
</back>
</article>